Axel Van Der Gucht1, Mehdi Aoun Sebaiti2,3, Eric Guedj4, Jessie Aouizerate3,5,6, Sabrina Yara3, Romain K Gherardi3,5,6, Eva Evangelista7, Julia Chalaye7, Anne-Ségolène Cottereau7, Antoine Verger8, Anne-Catherine Bachoud-Levi2,9, Mukedaisi Abulizi7, Emmanuel Itti7, François-Jérôme Authier3,5,6. 1. Department of Nuclear Medicine, H. Mondor Hospital, Assistance Publique-Hôpitaux de Paris/Paris-Est University, Créteil, France axel.vandergucht@gmail.com. 2. Deparment of Neurology, H. Mondor Hospital, Assistance Publique-Hôpitaux de Paris/Paris-Est University, Créteil, France. 3. INSERM U955-Team 10, Créteil, France. 4. Department of Nuclear Medicine, CHU La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France. 5. Department of Pathology, H. Mondor Hospital, Assistance Publique-Hôpitaux de Paris/Paris-Est University, Créteil, France. 6. Reference Center for Neuromuscular Disorders, H. Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France. 7. Department of Nuclear Medicine, H. Mondor Hospital, Assistance Publique-Hôpitaux de Paris/Paris-Est University, Créteil, France. 8. Nuclear Medecine & Nancyclotep Experimental Imaging Platform, CHU Nancy, Nancy, France; and. 9. INSERM U955-Team 1, Créteil, France.
Abstract
The aim of this study was to characterize brain metabolic abnormalities in patients with macrophagic myofascitis (MMF) and the relationship with cognitive dysfunction through the use of PET with 18F-FDG. Methods: 18F-FDG PET brain imaging and a comprehensive battery of neuropsychological tests were performed in 100 consecutive MMF patients (age [mean ± SD], 45.9 ± 12 y; 74% women). Images were analyzed with statistical parametric mapping (SPM12). Through the use of analysis of covariance, all 18F-FDG PET brain images of MMF patients were compared with those of a reference population of 44 healthy subjects similar in age (45.4 ± 16 y; P = 0.87) and sex (73% women; P = 0.88). The neuropsychological assessment identified 4 categories of patients: those with no significant cognitive impairment (n = 42), those with frontal subcortical (FSC) dysfunction (n = 29), those with Papez circuit dysfunction (n = 22), and those with callosal disconnection (n = 7). Results: In comparison with healthy subjects, the whole population of patients with MMF exhibited a spatial pattern of cerebral glucose hypometabolism (P < 0.001) involving the occipital lobes, temporal lobes, limbic system, cerebellum, and frontoparietal cortices, as shown by analysis of covariance. The subgroup of patients with FSC dysfunction exhibited a larger extent of involved areas (35,223 voxels vs. 13,680 voxels in the subgroup with Papez circuit dysfunction and 5,453 voxels in patients without cognitive impairment). Nonsignificant results were obtained for the last subgroup because of its small population size. Conclusion: Our study identified a peculiar spatial pattern of cerebral glucose hypometabolism that was most marked in MMF patients with FSC dysfunction. Further studies are needed to determine whether this pattern could represent a diagnostic biomarker of MMF in patients with chronic fatigue syndrome and cognitive dysfunction.
The aim of this study was to characterize brain metabolic abnormalities in patients with macrophagic myofascitis (MMF) and the relationship with cognitive dysfunction through the use of PET with 18F-FDG. Methods:18F-FDG PET brain imaging and a comprehensive battery of neuropsychological tests were performed in 100 consecutive MMF patients (age [mean ± SD], 45.9 ± 12 y; 74% women). Images were analyzed with statistical parametric mapping (SPM12). Through the use of analysis of covariance, all 18F-FDG PET brain images of MMF patients were compared with those of a reference population of 44 healthy subjects similar in age (45.4 ± 16 y; P = 0.87) and sex (73% women; P = 0.88). The neuropsychological assessment identified 4 categories of patients: those with no significant cognitive impairment (n = 42), those with frontal subcortical (FSC) dysfunction (n = 29), those with Papez circuit dysfunction (n = 22), and those with callosal disconnection (n = 7). Results: In comparison with healthy subjects, the whole population of patients with MMF exhibited a spatial pattern of cerebral glucose hypometabolism (P < 0.001) involving the occipital lobes, temporal lobes, limbic system, cerebellum, and frontoparietal cortices, as shown by analysis of covariance. The subgroup of patients with FSC dysfunction exhibited a larger extent of involved areas (35,223 voxels vs. 13,680 voxels in the subgroup with Papez circuit dysfunction and 5,453 voxels in patients without cognitive impairment). Nonsignificant results were obtained for the last subgroup because of its small population size. Conclusion: Our study identified a peculiar spatial pattern of cerebral glucose hypometabolism that was most marked in MMF patients with FSC dysfunction. Further studies are needed to determine whether this pattern could represent a diagnostic biomarker of MMF in patients with chronic fatigue syndrome and cognitive dysfunction.
Authors: S Sahbai; P Kauv; M Abrivard; P Blanc-Durand; M Aoun-Sebati; B Emsen; A Luciani; J Hodel; F-J Authier; E Itti Journal: Eur J Nucl Med Mol Imaging Date: 2018-12-14 Impact factor: 9.236
Authors: Axel Van Der Gucht; Mukedaisi Abulizi; Paul Blanc-Durand; Mehdi Aoun-Sebaiti; Berivan Emsen; Romain K Gherardi; Antoine Verger; François-Jérôme Authier; Emmanuel Itti Journal: Medicine (Baltimore) Date: 2017-09 Impact factor: 1.889
Authors: Paul Blanc-Durand; Axel Van Der Gucht; Eric Guedj; Mukedaisi Abulizi; Mehdi Aoun-Sebaiti; Lionel Lerman; Antoine Verger; François-Jérôme Authier; Emmanuel Itti Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240